ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 60

The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis

Christian A. Waimann1, Gustavo Citera2, Hernan Maldonado Ficco3, Oscar L. Rillo4, Mariana Benegas5, Rafael Chaparro del Moral6, Antonio Catalan Pellet7, Anastasia Secco8, Lucila Marino9, Alberto Berman10, Horacio Berman10, Ana Lucía Barbaglia11, Juan Carlos Marcos12, Josefina Marcos13, Francisco Caeiro14, Maria Haye Salinas15, Ana C. Alvarez16, Enrique Soriano17, Zaida Bedran18, Sergio Paira19, Federico Ceccato19, Gabriela Salvatierra20, Ana Quinteros21, Emilio Buschiazzo22 and Edson Javier Velozo23, 1Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, 4Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, 5Rheumatology, Hospital Tornu, Buenos Aires, Argentina, 6Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 7Rheumatology, Hospital Rivadavia, Buenos Aires, Argentina, 8Rheumathology, Hospital Bernardino Rivadavia, Buenos aires, Argentina, 9Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 10Centro Medico Privado de Reumatologia, Tucuman, Argentina, 11Rheumatology, Hospital Padilla, Tucuman, Argentina, 12Rheumatology, Hospital San Martin, La Plata, Argentina, 13Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 14Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 15Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, 16Rheumatology, Hospital Privado, Córdoba, Argentina, 17Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 18Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 19Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, 20Rheumatology, Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, 21Centro Integral de Reumatología, Tucumán, Argentina, 22Rheumatology, Hospital Señor del Milagro, Salta, Argentina, 23Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Economics, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including Latin America are limited, and the real burden of inflammatory arthritis in this population is unknown. The aim of our study was to evaluate the impact of disease activity on health-related quality of life (HRQOL) using a large cohort of Argentinian patients with early inflammatory arthritis.

Methods:   We included patients with diagnosis of early RA (American College of Rheumatology 1987′ criteria) or undifferentiated arthritis (UA) belonging to CONAART (Consorcio Argentino de Artritis Temprana – Argentine Consortium for Early Arthritis). CONAART is a prospective cohort of Argentinian patients with diagnosis of early arthritis (<2 years of disease duration). Data are collected every 3 months, including Health Assessment Questionnaire (HAQ), Clinical Disease Activity Index (CDAI) and pharmaco-economic data.  The generic EuroQoL (EQ-5D) was derived from HAQ and patient’s visual analogue scale of pain using previously validated regression models. Patients were stratified and compared according to diagnosis and disease activity levels (CDAI). All comparisons were adjusted for sex, age and comorbidities.

Results: We included 777 patients (RA=628; UA=149). Mean follow-up 14.5 ± 10.1 months (990 patients-year). Mean age was 48 ± 14 years, 82% were female and disease duration was 8.6 ± 6.3 months. On baseline visit CDAI and HAQ were 24.6 ± 14.4 and 1.2 ± 0.9, respectively. Mean EQ-5D score during follow-up was 0.74 ± 0.13. No difference regarding HRQL was observed between RA and UA (0.73 ± 0.12 and 0.75 ± 0.13, respectively). EQ-5D showed a negative correlation with disease activity (rho spearman=-0.74, p<0.0001).  Mean EQ-5D in patients in remission was 0.91 ± 0.04, low disease activity=0.82 ± 0.81, moderate disease activity=0.72 ± 0.09 and high disease activity=0.61 ± 0.11 (Graph 1). Considering remission as the ideal situation,   patients with early RA or UA in low disease activity entail a disease burden of 0.07 (95%CI= 0.06 – 0.08) quality-adjusted life-years (QALYs) after one year of follow-up. In similar conditions, patients with moderate disease activity lose 0.17 (95%CI= 0.16 – 0.18) QALYs, and those with high disease activity lose 0.28 (95%CI= 0.27 – 0.30) QALYs.   

Conclusion: Regardless of the diagnosis of UA or RA, patients with early inflammatory arthritis and active disease inflict a substantial disease burden. The impact of arthritis in HRQL showed a linear relationship with disease activity level. This remarks the importance of an early and aggressive treatment in patient with this condition.           

Graph 1. Health-related quality of life stratified by disease activity and diagnosis 


Disclosure:

C. A. Waimann,

Pfizer Inc,

2;

G. Citera,

Pfizer Inc,

2;

H. Maldonado Ficco,

Pfizer Inc,

2;

O. L. Rillo,

Pfizer Inc,

2;

M. Benegas,

Pfizer Inc,

2;

R. Chaparro del Moral,

Pfizer Inc,

2;

A. Catalan Pellet,

Pfizer Inc,

2;

A. Secco,

Pfizer Inc,

2;

L. Marino,

Pfizer Inc,

2;

A. Berman,

Pfizer Inc,

2;

H. Berman,

Pfizer Inc,

2;

A. L. Barbaglia,

Pfizer Inc,

2;

J. C. Marcos,

Pfizer Inc,

2;

J. Marcos,

Pfizer Inc,

2;

F. Caeiro,

Pfizer Inc,

2;

M. Haye Salinas,

Pfizer Inc,

2;

A. C. Alvarez,

Pfizer Inc,

2;

E. Soriano,

Pfizer Inc,

2;

Z. Bedran,
None;

S. Paira,

Pfizer Inc,

2;

F. Ceccato,

Pfizer Inc,

2;

G. Salvatierra,

Pfizer Inc,

2;

A. Quinteros,

Pfizer Inc,

2;

E. Buschiazzo,

Pfizer Inc,

2;

E. J. Velozo,

Pfizer Inc,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-burden-of-early-arthritis-in-latin-america-utility-analysis-using-patient-level-data-from-the-argentinian-consortium-for-early-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology